Intraocular pressure elevation after injection of triamcinolone acetonide: a multicenter retrospective case-control study.
OBJECTIVE
To determine the risk factors for intraocular pressure (IOP) elevation after the injection of triamcinolone acetonide (TA).


METHODS
Retrospective interventional case-control study.


METHODS



METHODS
Multicenter.


METHODS
Four hundred and twenty-seven patients.


METHODS
Intraocular pressure levels after TA treatment by the sub-Tenon capsule injection (STI; 12 mg, 20 mg, or 40 mg), intravitreal injection (IVI; 4 mg or 8 mg), or the combination of STI (20 mg) and IVI (4 mg), and IOP levels after two TA treatments.


METHODS
Risk factors for IOP levels of 24 mm Hg or higher.


RESULTS
Younger age (hazards ratio [HR], 0.96/year; P < .0001), IVI (HR, 1.89/year; P < .0001), and higher baseline IOP (HR, 1.15/mm Hg; P = .003) were identified as risk factors. Dose dependency was shown in STI-treated eyes (HR, 1.07/mg; P = .0006), as well as after IVI (HR, 1.64/mg; P = .013). The combination of STI and IVI was a significant risk factor (HR, 2.27; P = .003) compared with STI alone. In eyes receiving two TA treatments, IVI (HR, 2.60; P = .010), higher IOP elevation after the first injection (HR, 1.18/mm Hg; P = .011), and increased dosage of STI (HR, 1.07/mm Hg; P = .033) were risk factors.


CONCLUSIONS
Younger age, higher baseline IOP, IVI, and increased TA dosage were associated with TA-induced IOP elevation. IOP elevation after repeated TA injection was frequently associated with eyes treated with IVI, high IOP elevation after the first injection, and high doses of STI.
Inatani
Masaru
M
Department of Ophthalmology and Visual Science, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan. inatani@fc.kuh.kumamoto-u.ac.jp
Iwao
Keiichiro
K
Kawaji
Takahiro
T
Hirano
Yoshio
Y
Ogura
Yuichiro
Y
Hirooka
Kazuyuki
K
Shiraga
Fumio
F
Nakanishi
Yoriko
Y
Yamamoto
Hiroyuki
H
Negi
Akira
A
Shimonagano
Yuka
Y
Sakamoto
Taiji
T
Shima
Chieko
C
Matsumura
Miyo
M
Tanihara
Hidenobu
H
D000368:Aged; D016022:Case-Control Studies; D003238:Connective Tissue / Q000187:drug effects; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced*; D012164:Retinal Diseases / Q000188:drug therapy; D012189:Retrospective Studies; D012307:Risk Factors; D014065:Tonometry, Ocular; D014222:Triamcinolone Acetonide / Q000009:adverse effects*
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide